Skip to main content
Log in

Reply to ‘Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia’ by Dr Laurenti et al.

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Laurenti L, Tarnani M, Efremov DG, Chiusolo P, De Padua L, Sica S et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007, in press.

  2. Karlsson C, Hansson H, Celsing F, Lundin J . Treatment of severe refractory autoimmune hemolytic anemia (AIHA) in B-cell chronic lymphocytic leukemia (B-CLL) with alemtuzumab humanized CD52 monoclonal antibody. Leukemia 2007; 21: 511–514.

    Article  CAS  Google Scholar 

  3. Hale G, Rebello P, Brettman L, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundin, J. Reply to ‘Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia’ by Dr Laurenti et al.. Leukemia 21, 1821 (2007). https://doi.org/10.1038/sj.leu.2404704

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404704

  • Springer Nature Limited

Navigation